Findings may prevent early loss of synapses in Alzheimer’s
By Peter Bochner
One of the first signs of Alzheimer’s disease is the loss of synapses — the structures that connect neurons in the brain. Synapses are required for all brain functions, particularly for learning and memory. In Alzheimer’s patients, most of the damage appears to take place in the part of the brain that is essential in forming memories.
“In Alzheimer’s disease, this loss of synapses occurs very early on, when people still only have mild cognitive impairment, and long before the nerve cells themselves die,” said Vladimir Sytnyk, the leader of a research team at University of New South Wales, Australia.
If you’re looking for drugs to treat potency, you may want to consider an online pharmacy. Online pharmacies offer fast delivery and can sometimes provide drugs without a prescription. Viagra, Cialis, Levitra, and Kamagra are all drugs that are used to treat erectile dysfunction, and they are available at many online pharmacies. These drugs work by increasing blood flow to the penis, which helps to achieve and maintain an erection https://www.andreasapotek.com. Viagra is the most well-known of these drugs, but Cialis and Levitra are also popular options. Kamagra is a generic form of Viagra that is often cheaper than the brand-name version. Whatever drug you choose, be sure to consult with a doctor before taking it.
Sytnyk’s team recently revealed that it had identified a new molecular mechanism that plays a major role in the connections between synapses. The protein, called neural cell adhesion molecule 2 (NCAM2), has been shown to occur in low levels in the brains of Alzheimer’s patients.
Mice and laboratory studies have shown that NCAM2 is broken down by beta-amyloid proteins, which are the abnormal clumps that build up in the brains of people with Alzheimer’s. According to Sytnyk, his team’s research shows that the loss of NCAM2 results from the toxic effects of beta-amyloid.
The research “opens up a new avenue for research on possible treatments that can prevent the destruction of NCAM2 in the brain,” added Sytnyk. If the destruction of NCAM2 can be prevented, this could lead to earlier diagnosis of Alzheimer’s and new treatments for the condition in its early stages.
The study was published in the journal Nature Communications.
Peter Bochner is a writer and editor for subjects related to information technology and medicine. He has worked on such publications as Computerworld, Asian Sources and the Journal of Alzheimers Disease, served as editor for several TechTarget websites, and has written for several high-tech research firms. In addition, he served as editor for the recently published book Aspertools: The Practical Guide for Understanding and Embracing Asperger’s, Autism Spectrum Disorder and Neurodiversity, by Harold S. Reitman, M.D.